Cimzia related Press Releases
Surveyed Gastroenterologists Will Treat Fewer Crohn's Disease Patients With Remicade, While the Percentage of Biologics-Treated
Humira Has Achieved the Most Favorable Tier Placement Among Biologics for Crohn's Disease and Ulcerative Colitis, According to a New Report from Decision ResourcesWALTHAM, Mass., April 7 /PRNewswire/ Read more...
Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease Administered every four weeks, UCB's pegylated anti-TNFa offers new treatment option for patients with moderate to Read more...
PRESS RELEASE: UCB Group Drug Cimzia Faces EU Delay, Shares Plunge
UCB Group Drug Cimzia Faces EU Delay, Shares Plunge Brussels (BELGIUM), November 16, 2007 at 7:00 am CET - UCB announced today that it has been informed by the European Medicines Agency (EMEA) that Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
